CoChat
Sign Up
Cited by 104Sexual function and dysfunction studiesSexuality, Behavior, and TechnologySex work and related issues

Managing female sexual dysfunction

Open access
Buster, John E.·2013·Fertility and Sterility
DOI 10.1016/j.fertnstert.2013.08.026
Open this paper in CoChat — free accountOpen PDF

Abstract

Female sexual dysfunctions (FSDs) range from short-term aggravations to major emotional disturbances adversely affecting family and workplace. This review highlights diagnosis and management of the four most widely diagnosed FSDs. It initially focuses on hypoactive sexual desire disorder (HSDD) as a driving force at the heart of all other FSDs; nothing happens without sexual desire. Successful resolution of HSDD frequently facilitates resolution of other disorders. Central to understanding HSDD is the impact of aging female sexual endocrinology and its effect on both prevalence and expression patterns of FSD. Advances in this field have enabled introduction of some the most effective treatments yet described for HSDD. Sexual arousal disorder, though commonly affected by the same factors as HSDD, is heavily associated with psychotropic drugs and mood elevators. Orgasmic disorder is frequently the downstream result of other sexual dysfunctions, particularly HSDD, or the result of a major psychosexual trauma. Successful management of the underlying disorder often resolves orgasmic disorder. Sexual pain disorder is frequently the result of a gynecologic disorder, such as endometriosis, that can be substantially managed through successful treatment of that disorder. This article ends with the article's most important note: how to initiate the conversation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.fertnstert.2013.08.026

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Female sexual dysfunction or loss of sexual freedom brought on by SA/CSB-induced betrayal can manifest as decreased sexual desire, declining arousal, limited orgasmic function, and frequent discomfort during sexual activity.

    “Female sexual dysfunction or loss of sexual freedom brought on by SA/CSB-induced betrayal can manifest as decreased sexual desire, declining arousal, limited orgasmic function, and frequent discomfort during sexual activity (Buster, 2013;Minwalla, 2021aMinwalla, , 2021b;;Weiss, 2019).”

    From “Your Addiction, her Sexual Suffering”—A Qualitative Inquiry into the Effects of Compulsive Sexual Behaviors on Intimate Female Partners (2025) · cites this paper as Buster, 2013

    The sections “How to Manage Female Sexual Dysfunctions” and “Sexual” describe problems of desire, arousal, orgasm, and sexual pain. They do not establish that SA/CSB-induced betrayal causes those problems or a loss of sexual freedom; searches for betrayal and infidelity found no such discussion in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 62

  1. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gy- necol 2008;112:970-8.
  2. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, et al. Report of the International consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000;163:888-93.
  3. Fakhri A, Pakpour AH, Burri A, Morshedi H, Zeidi IM. The Female Sexual Function Index: translation and validation of an Iranian version. J Sex Med 2012;9:514-23.
  4. Takahashi M, Inokuchi T, Watanabe C, Saito T, Kai I. The Female Sexual Function Index (FSFI): development of a Japanese version. J Sex Med 2011;8:2246-54.
  5. Ogbera AO, Chinenye S, Akinlade A, Eregie A, Awobusuyi J. Frequency and correlates of sexual dysfunction in women with diabetes mellitus. J Sex Med 2009;6:3401-6.
  6. Escajadillo-Vargas N, Mezones-Holguín E, Castro-Castro J, C ordova- Marcelo W, Bl€ umel JE, P erez-L opez FR, Chedraui P. Sexual dysfunction risk and associated factors in young Peruvian university women. J Sex Med 2011;8:1701-9.
  7. Oksuz E, Malhan S. Prevalence and risk factors for female sexual dysfunction in Turkish women. J Urol 2006;175:654-8.
  8. Hornsby PJ. Biosynthesis of DHEAS by the human adrenal cortex and its age- related decline. Ann N Y Acad Sci 1995;774:29-46.
  9. Haselton MG, Mortezaie M, Pillsworth EG, Bleske-Reschek A, Frederick DA. Ovulatory shifts in human female ornamentation: near ovulation, women dress to impress. Horm Behav 2007;51:40-5.
  10. Gildersleeve KA, Haselton MG, Larson CM, Pillsworth EG. Body odor attrac- tiveness as a cue of impending ovulation in women: evidence from a study using hormone-confirmed ovulation. Horm Behav 2012;61:157-66.
  11. Fischer J, Semple S, Fickenscher G, J€ urgens R, Kruse E, Heistermann M, Amir O. Do women's voices provide cues of the likelihood of ovulation? The importance of sampling regime. Rev Obstet Gynecol 2012;5:16-27.
  12. Guay AT, Jacobson J. Decreased free testosterone and dehydroe- piandrosterone-sulfate (DHEA-S) levels in women with decreased libido. J Sex Marital Ther 2002;28:129-42.
  13. Rotter JI, Wong FL, Lifrak ET, Parker LN. A genetic component to the varia- tion of dehydroepiandrosterone sulfate. Metabolism 1985;34:731-6.
  14. Ambler DR, Bieber E, Diamond MP. Sexual function in elderly women: a re- view of current literature. J Am Med Dir Assoc 2013;8610:78-9.
  15. Lochlainn MN, Kenny RA. Sexual activity and aging. J Am Med Dir Assoc 2013;14:565-72.
  16. Van der Stege JG, Groen H, van Zadelhoff SJ, Lambalk CB, Braat DD, Kasteren YM, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008;15:23-31.
  17. Basson R. Female sexual dysfunction in hypopituitarism. Lancet 2007; 370:737.
  18. Latif EZ, Diamond MP. Arriving at the diagnosis of female sexual dysfunc- tion. Fertil Steril 2013;100:898-904.
  19. Kennedy SH, Rizvi S. Sexual dysfunction, depression and the impact of anti- depressants. J Clin Psychopharmacol 2009;29:157-64.
  20. Zemishlany Z, Weizman A. The impact of mental illness on sexual dysfunc- tion. Adv Psychosom Med 2008;29:89-106.
  21. Association of Reproductive Health Professionals. Women's sexual health in midlife and beyond. ARHP Clin Proc 2005;5:8-12.
  22. Serin I, Ozcelik B, Basbu g M, Aygen E, Kula M, Erez R. Long-term effects of continuous oral and transdermal estrogen replacement therapy on sex hor- mone binding globulin and free testosterone levels. Eur J Obstet Gynecol Re- prod Biol 2001;99:222-5.
  23. Buster JE. Transdermal menopausal hormone therapy: delivery through skin changes the rules. Expert Opin Pharmacother 2010;11:1489-99.
  24. Falk SJ, Dizon DS. Sexual dysfunction in women with cancer. Fertil Steril 2013;100:916-21.
  25. Laan E, Both S. Sexual desire and arousal disorders in women. Adv Psycho- som Med 2011;31:16-34.
  26. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women, principle results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
  27. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, et al. Conjugated equine oestrogen and breast cancer incidence and mortal- ity in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012;13:476-86.
  28. Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, et al, Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen adminis- tration. Circulation 2005;112:3495-500.
  29. Pelletier G, Ouellet J, Martel C, Labrie F. Effects of ovariectomy and dehydro- epiandrosterone (DHEA) on vaginal wall thickness and innervation. J Sex Med 2012;9:2525-33.
  30. Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 2007;92:3040-3.
  31. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-8.
  32. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch, Rodenberg CA, et al. Testosterone patch for low sexual desire in surgi- cally menopausal women: a randomized trial. Obstet Gynecol 2005; 105:944-52.
  33. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, et al. Safety and efficacy of a testosterone patch for the treat- ment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005; 165:1571-2.
  34. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2006;13:770-9.
  35. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, Braunstein GD, et al. Testosterone for low libido in postmenopausal women not taking es- trogen. N Engl J Med 2008;359:2005-17.
  36. Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden J, Lodhi I, et al. Testos- terone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 2010;13:121-31.
  37. Bloemers J, van Rooij K, Poels S, Goldstein I, Everaerd W, Koppeschaar H, et al. Toward personalized sexual medicine (part 1): integrating the ''dual control model'' into differential drug treatments for hypoactive sexual desire disorder and female sexual arousal disorder. J Sex Med 2013;10:791-809.
  38. North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of the North American Meno- pause Society. Menopause 2005;12:496-511.
  39. Shufelt CL, Braunstein GD. Safety of testosterone use in women. Maturitas 2009;63:63-6.
  40. Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, et al, DAISY Trial Investigators. Treatment of hypoactive sexual desire disorder in premeno- pausal women: efficacy of flibanserin in the DAISY study. J Sex Med 2012;9:793-804.
  41. Katz M, Derogatis LR, Ackerman R, Hedges P, Lesko L, Garcia M Jr, Sand M, BEGONIA Trial Investigators. Efficacy of Flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med 2013;10:1807-15.
  42. Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996;103:351-8.
  43. Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med 2008;5:887-97.
  44. Wilson SK, Delk JR 2nd, Billups KL. Treating symptoms of female sexual arousal disorder with the Eros clitoral therapy device. J Gend Specif Med 2001;4:54-8.
  45. Islam A, Mitchel J, Rosen R, Phillips N, Ayers C, Ferguson D, et al. Topical al- prostadil in the treatment of female sexual arousal disorder: a pilot study. J Sex Marital Ther 2001;27:531-40.
  46. Chivers ML, Rosen RC. Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms? J Sex Med 2010;7: 858-72.
  47. Ferguson DM, Steidle CP, Singh GS, Alexander JS, Weihmiller MK, Crosby MG. Randomized, placebo-controlled, double blind, crossover design trial of the efficacy and safety of Zestra for Women in women with and without female sexual arousal disorder. J Sex Marital Ther 2003;29: 33-44.
  48. Rellini AH, Clifton J. Female orgasmic disorder. Adv Psychosom Med 2011; 31:35-56.
  49. Meston CM, Hull E, Levin RJ, Sipski M. Disorders of orgasm in women. J Sex Med 2004;1:66-8.
  50. Boyer SC, Goldfinger C, Thibault-Gagnon S, Pukall CF. Management of fe- male sexual pain disorders. Adv Psychosom Med 2011;31:83-104.
  51. Fritzer N, Haas D, Oppelt P, Renner S, Hornung D, W€ olfler M, et al. More than just bad sex: sexual dysfunction and distress in patients with endome- triosis. Eur J Obstet Gynecol Reprod Biol 2013;169:392-6.
  52. Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 2006;108:915-23.
  53. Seo JT, Choe JH, Lee WS, Kim KH. Efficacy of functional electrical stimulation-biofeedback with sexual cognitive-behavioral therapy as treat- ment of vaginismus. Urology 2005;66:77-81.
  54. Rosenbaum T. Addressing anxiety in vivo in physiotherapy treatment of women with severe vaginismus: a clinical approach. J Sex Marital Ther 2011;37:89-93.
  55. Park AJ, Paraiso MF. Successful use of botulinum toxin type a in the treatment of refractory postoperative dyspareunia. Obstet Gynecol 2009;114:484-7.
  56. Pacik PT. Vaginismus: review of current concepts and treatment using botox injections, bupivacaine injections, and progressive dilation with the patient under anesthesia. Aesthetic Plast Surg 2011;35:1160-4.
  57. Pacik PT. Botox treatment for vaginismus. Plast Reconstr Surg 2009;124: 455e-6e.
  58. Shifren JL, Johannes CB, Monz BU, Russo PA, Bennett L, Rosen R. Help- seeking behavior of women with self-reported distressing sexual problems. J Women's Health (Larchmt) 2009;18:461-8.
  59. Solursh DS, Ernst JL, Lewis RW, Prisant LM, Mills TM, Solursh LP, et al. The human sexuality education of physicians in North American medical schools. Int J Impot Res 2003;15:41-5.
  60. Humphrey S, Nazareth I. GPs views on their management of sexual disfunc- tion. J Fam Pra 2001;18:516-8.
  61. Bachmann GA, Leiblum SR, Grill J. Brief sexual inquiry in gynecologic prac- tice. Obstet Gynecol 1989;73:425-7.
  62. Kingsberg SA, Janata JW. Female sexual disorders: assessment, diagnosis, and treatment. Urol Clin North Am 2007;34:497-506.

Cited by

Sorted by citations

Authors
Buster, J. E.
Affiliations
Women & Infants Hospital of Rhode Island (US)
Corresponding author
Buster, John E.
Venue
Fertility and Sterility
Publisher
Elsevier BV
Published
2013-10
Volume
100
Issue
4
Pages
905-915
ISSN
0015-0282 (ISSN-L)
DOI
10.1016/j.fertnstert.2013.08.026
OpenAlex
W2055233354
Cited by
104
References
8
Citations by year
2026: 6 · 2025: 8 · 2024: 8 · 2023: 4 · 2022: 2 · 2021: 12 · 2020: 9 · 2019: 10 · 2018: 9 · 2017: 11 · 2016: 7 · 2015: 9 · 2014: 9
FWCI
1.14
Type
journal article
Language
en
Open access
Licence
Locations
  • Fertility and Sterility (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
  • Social Sciences › Psychology › Clinical Psychology › Sexuality, Behavior, and Technology
  • Social Sciences › Sociology and Political Science › Sex work and related issues
Keywords
female sexual dysfunction, hypoactive sexual desire disorder, sexual arousal disorders, orgasm disorders, sexual pain disorders, aging, psychotropic drugs, endometriosis, diagnosis, treatment
MeSH terms
Female, Humans, Sexual Behavior, Sexual Dysfunction, Physiological, Treatment Outcome, Sexual Dysfunctions, Psychological, Recovery of Function, Reproductive Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review